Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [25][31]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 5.06% from March 13 to March 26, 2026, which is approximately 0.6 percentage points lower than the index [10][11]. - All sub-sectors within the industry recorded negative returns during the same period, with the medical research outsourcing and in vitro diagnostics sectors experiencing the least decline at 1.97% and 2.84%, respectively. The hospital and blood products sectors had the largest declines at 7.71% and 6.95% [11][12]. - Approximately 17% of stocks in the industry recorded positive returns, while about 83% experienced negative returns during the reporting period [12][15]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 44.86 times as of March 26, 2026, which indicates a decrease in industry valuation [16][25]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 5.06% from March 13 to March 26, 2026 [10]. - All sub-sectors recorded negative returns, with the medical research outsourcing and in vitro diagnostics sectors showing the smallest declines [11]. - About 17% of stocks in the industry had positive returns, with the top performer being Meinuohua, which increased by 54.47% [12][15]. 2. Industry News - A significant event was the announcement of the results for the centralized procurement of coronary intervention balloon medical consumables in Henan, which saw all participating companies selected, reflecting a shift towards a "price anchor" concept [23]. - The National Health Commission issued guidelines for evaluating the clinical application of medical technologies, emphasizing the importance of quality and safety in healthcare [20][22]. 3. Company Announcements - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. received a CEP certificate for its sulfanilamide raw material, indicating compliance with European quality standards. The market size for this product in China is approximately 428 million RMB, with a year-on-year growth of 3.1% [24]. 4. Weekly Industry Perspective - The report suggests that the investment risk-reward ratio for the innovative drug sector is improving, with several companies expected to exceed performance expectations during the earnings disclosure period. Key sectors to watch include medical devices, pharmaceutical commerce, aesthetic medicine, scientific services, hospital and diagnostic services, traditional Chinese medicine, innovative drugs, biological products, and CXO services [27][28].